greeksoup/ stock research

GeneDx Holdings (WGS) Q3 FY2026 earnings: revenue $123 million, up 5.4% on the year

GeneDx Holdings Corp. (WGS) reported revenue of $123 million for Q3 FY2026, the quarter ended 30 September 2026, up 5.4% on the same quarter a year earlier. Net income was -$12 million, and diluted earnings per share $-0.41. The figures are the company's own, from the 10-Q it filed with the SEC on 9 November 2026.

Revenue
$123 million
+5.4% on the year · +7.6% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
-8.5%
-2.8% a year earlier
Q4 FY2024Q3 FY2026
Net income
-$12 million
Q4 FY2024Q3 FY2026
Diluted EPS
-$0.41
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 raised, 2 lowered, 6 new, 1 kept.

  • Revenue rose 5% to $123.1 million: The company reported revenue of $123.1 million, up 5% from $116.7 million a year earlier and up from $114.4 million in the second quarter.
  • Exome and genome volume rose 25%: Exome and genome test result volume reached 32,134 tests, up 25% from a year earlier, with accession growth of 28%.
  • Adjusted gross margin reached 72%: Adjusted gross margin was 72%, up from 70% in the second quarter and compared with 74% a year earlier. GAAP gross margin was 70%.
Read the earnings call summary

Income statement (profit and loss)

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Revenue123114117+7.6%+5.4%
Cost of revenue37.036.232.2+2.3%+15.0%
Gross profit86.178.284.5+10.0%+1.8%
Gross margin69.9%68.4%72.4%
Research and development17.419.719.8-11.7%-12.4%
Selling, general and administrative79.176.067.9+4.1%+16.4%
Operating income-10.4-17.5-3.3
Operating margin-8.5%-15.3%-2.8%
Interest expense1.81.20.6+50.1%+216.5%
Pre-tax income-12.3-18.3-7.4
Income tax0.0-0.50.2-89.5%
Net income-12.3-17.7-7.6
Net margin-10.0%-15.5%-6.5%
Diluted EPS-$0.41-$0.60-$0.27
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Operating cash flow-10.6-29.015.8
Capital expenditure5.210.16.2-48.3%-15.4%
Free cash flow-15.8-39.19.6
Free cash flow margin-12.9%-34.2%8.2%
Cash from investing-7.4-5.6-4.7
Cash from financing53.81.010.8+5,257.1%+400.0%
Depreciation and amortisation3.33.12.4+6.5%+37.5%
Share-based compensation8.36.310.6+30.1%-22.0%
Diluted shares, weighted30m30m29m+0.6%+3.8%
Shares outstanding at period end30m30m29m+0.5%+3.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Shareholders' equity245244292+0.2%-16.3%
Debt15010054.8+50.0%+173.5%
Other liabilities132137147-4.0%-10.2%
Total liabilities and equity526481494+9.3%+6.6%
Fixed assets53.554.3n/a-1.4%
Goodwill1.61.612.80.0%-87.2%
Intangible assets138141173-2.6%-20.2%
Investments74.072.259.1+2.4%+25.2%
Cash and equivalents96.160.396.0+59.4%+0.2%
Receivables92.183.660.9+10.2%+51.2%
Inventory21.717.810.6+21.8%+105.3%
Other assets49.650.281.9-1.1%-39.4%
Total assets526481494+9.3%+6.6%

Questions

What was GeneDx Holdings' revenue in Q3 FY2026?

GeneDx Holdings (WGS) reported revenue of $123 million for Q3 FY2026, the quarter ended 30 September 2026, up 5.4% on the same quarter a year earlier.

How much did GeneDx Holdings earn in Q3 FY2026?

Net loss for Q3 FY2026 was $12 million, and the diluted loss per share $0.41.

When did GeneDx Holdings report Q3 FY2026 results?

GeneDx Holdings filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 9 November 2026.

Quarterly results, the last 20 quarters

Q4 FY2021 †Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025 †Q2 FY2025 †Q3 FY2025 †Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue57.853.936.283.261.443.148.753.357.462.470.576.995.687.1103117121102114123
Cost of revenue60.648.365.869.777.727.929.928.026.725.027.629.029.428.631.832.236.734.036.237.0
Gross profit-2.85.6-29.613.5-16.315.218.825.330.837.443.047.866.258.570.984.584.368.278.286.1
Gross margin-5%10%-82%16%-27%35%39%47%54%60%61%62%69%67%69%72%70%67%68%70%
R&D22.221.327.213.424.414.617.114.312.211.610.911.711.612.615.119.824.519.819.717.4
SG&An/an/an/an/an/an/an/an/an/an/an/an/an/a50.546.967.9n/a74.676.079.1
Operating income-116-89.3-163-90.8-325-60.4-51.6-43.0-25.6-13.7-10.6-7.88.8-4.69.0-3.3-14.2-57.5-17.5-10.4
Operating margin-200%-166%-450%-109%-530%-140%-106%-81%-45%-22%-15%-10%9%-5%9%-3%-12%-56%-15%-8%
Interest expense0.70.80.80.80.80.80.6n/an/a0.60.90.80.70.60.80.60.50.71.21.8
Pre-tax income-40.2-76.9-135-77.6-309-61.1-46.9-42.5-26.2-20.3-29.4-8.45.4-6.110.6-7.4-18.2-62.4-18.3-12.3
Tax raten/an/an/an/an/an/an/an/an/an/an/an/a-0%n/a-2%n/an/an/an/an/a
Net income-40.2-76.9-85.7-77.6-309-61.0-46.7-42.3-25.8-20.2-29.2-8.35.4-6.510.8-7.6-17.7-63.3-17.7-12.3
Net margin-70%-143%-237%-93%-503%-141%-96%-79%-45%-32%-41%-11%6%-7%11%-7%-15%-62%-16%-10%
Diluted EPSn/a-$10.23-$8.25-$6.60n/a-$3.04-$1.84-$1.64n/a-$0.78-$1.10-$0.31n/a-$0.23$0.36-$0.27-$0.61-$2.16-$0.60-$0.41
Operating cash flow-52.0-81.5-84.6-88.4-64.7-55.6-53.5-41.2-29.9-16.4-4.5-4.4-3.210.210.415.8-3.1-32.4-29.0-10.6
Capital expenditure5.11.41.42.22.20.02.80.12.40.41.40.63.06.12.46.24.36.510.15.2
Free cash flow-57.0-82.9-86.0-90.6-66.8-55.6-56.3-41.3-32.2-16.9-5.9-5.0-6.24.18.19.6-7.4-38.9-39.1-15.8
Shares outstanding7m7m12m12m356,75924m26m26m26m26m27m27m28m29m29m29m29m30m30m30m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 9 November 2026: the filing.